NeoGenomics (NASDAQ:NEO) had its price target hoisted by Scotiabank from $22.00 to $23.00 in a report published on Tuesday morning. The firm currently has an outperform rating on the medical research company’s stock.
Other research analysts have also recently issued research reports about the stock. Zacks Investment Research upgraded shares of NeoGenomics from a sell rating to a hold rating in a report on Thursday, March 1st. BidaskClub upgraded shares of NeoGenomics from a sell rating to a hold rating in a report on Monday, February 5th. CIBC set a $19.00 target price on shares of NeoGenomics and gave the stock a neutral rating in a report on Wednesday, January 3rd. Royal Bank of Canada set a $23.00 target price on shares of NeoGenomics and gave the stock an outperform rating in a report on Wednesday, January 3rd. Finally, ValuEngine cut shares of NeoGenomics from a hold rating to a sell rating in a report on Wednesday, March 7th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and five have issued a buy rating to the company’s stock. NeoGenomics presently has a consensus rating of Hold and a consensus target price of $17.29.
NeoGenomics (NEO) opened at $8.52 on Tuesday. The firm has a market cap of $685.09, a P/E ratio of -47.33, a PEG ratio of 4.84 and a beta of 0.47. NeoGenomics has a 1-year low of $7.08 and a 1-year high of $11.63. The company has a quick ratio of 1.99, a current ratio of 2.14 and a debt-to-equity ratio of 0.57.
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Fairpointe Capital LLC bought a new stake in NeoGenomics during the fourth quarter worth $2,464,000. Segall Bryant & Hamill LLC raised its position in NeoGenomics by 16.1% during the fourth quarter. Segall Bryant & Hamill LLC now owns 434,428 shares of the medical research company’s stock worth $3,849,000 after acquiring an additional 60,360 shares in the last quarter. MetLife Investment Advisors LLC bought a new stake in NeoGenomics during the fourth quarter worth $235,000. Stone Ridge Asset Management LLC bought a new stake in NeoGenomics during the fourth quarter worth $281,000. Finally, Guggenheim Capital LLC raised its position in shares of NeoGenomics by 46.6% in the fourth quarter. Guggenheim Capital LLC now owns 39,457 shares of the medical research company’s stock valued at $351,000 after purchasing an additional 12,538 shares during the period. 84.72% of the stock is currently owned by hedge funds and other institutional investors.
NeoGenomics Company Profile
NeoGenomics, Inc is an operator of a network of cancer-focused genetic testing laboratories. The Company operates in Laboratory Testing Segment. This segment delivers testing services to hospitals, pathologists, oncologists, other clinicians and researchers. It has laboratory locations in Ft. Myers and Tampa, Florida; Aliso Viejo, Fresno, Irvine, and West Sacramento, California; Houston, Texas and Nashville, and Tennessee.
Receive News & Ratings for NeoGenomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics and related companies with MarketBeat.com's FREE daily email newsletter.